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Abstract 
Importance: The angiotensin receptor neprilysin inhibitor sacubitril/valsartan reduced 
cardiovascular mortality, all-cause mortality, and hospitalizations compared to enalapril in the 
PARADIGM-HF trial.  Sacubitril/valsartan has been approved for use in heart failure with 
reduced ejection fraction in the United States and cost has been suggested as one factor that 
will influence use of this agent. 
 
Objective:  To estimate the cost-effectiveness of sacubitril/valsartan relative to enalapril in the 
United States. 
 
Design: Using inputs from the PARADIGM-HF trial data, a two-state Markov model was 
developed for the US setting. Risks of all-cause mortality and heart failure and non-heart failure 
hospitalizations were estimated with a 30 year time horizon. Quality of life was based on trial 
EQ-5D scores. Hospital costs combined Medicare and private insurance rates; medication costs 
included the wholesale acquisition cost for sacubitril/valsartan and enalapril. A discount rate of 
3% was used. Sensitivity analyses were performed on key inputs including: hospital costs, 
mortality benefit, hazard ratio for hospitalization reduction, drug costs, and quality of life 
estimates. 
 
Setting: United States population including both private payer and Medicare population. 
 
Participants: US population with heart failure with reduced ejection fraction with mean age of 
63.8 based on the PARADIGM-HF trial population. 
 
Main Outcomes: Hospitalizations, quality-adjusted life-years, costs, and incremental costs per 
quality-adjusted life-year gained. 
 
Results: Treatment with sacubitril/valsartan would result in 220 fewer heart failure admissions 
per 1000 patients treated over 30 years and incremental costs and quality adjusted life years 
(QALYs) of $35,208 and 0.78 respectively compared to enalapril, equating to an incremental 
cost-effectiveness ratio of $45,017/QALY for the base-case. Sensitivity analyses demonstrated 
ICERs ranging from $35,000 to $75,000/QALY. 
 
Conclusions and Relevance: For eligible patients with heart failure with reduced ejection 
fraction, sacubitril/valsartan increased life expectancy at an incremental cost-effectiveness ratio 
consistent with other high value accepted cardiovascular interventions. Sensitivity analyses 
demonstrated sacubitril/valsartan remains cost effective vs enalapril. 
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Introduction 
Heart failure (HF) is associated with considerable mortality, morbidity, and financial costs.  HF is 
the leading cause of admission to hospital in the United States and, with over 1 million 
admissions for HF annually in the United States1.  Total costs for HF are estimated between $24 
and $47 billion per year2. HF progression is aggravated by several detrimental neurohormonal 
pathways. Over the last three decades, therapies that inhibit or alter these pathways, including 
the use of angiotensin-converting enzyme inhibitors (ACEI), beta-blockers, and 
mineralocorticoid receptor antagonists, have improved mortality and morbidity of patients with 
HF with reduced ejection fraction (HFrEF).   
Sacubitril/valsartan (LCZ696), an angiotensin receptor neprilysin inhibitor, has been 
shown to reduce cardiovascular death and HF hospitalization in the PARADIGM-HF 
(Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and 
morbidity in Heart Failure) trial compared with enalapril.3 Sacubitril/valsartan has been approved 
for use in HFrEF in the United States and cost has been suggested as one factor that will 
influence use of this agent. We estimated the cost-effectiveness of this new medication relative 
to enalapril in the United States. 
 
METHODS 
HF disease simulation model strategies 
A two-state Markov model simulating HF was developed for the United States setting using 
PARADIGM-HF trial data comparing the two treatments: enalapril 10mg twice daily or 
sacubitril/valsartan 97/103mg twice daily.3,4 Using the results of the trial we simulated a 
population with equivalent characteristics as the trial population and then modelled additionally 
the costs and health consequences for the duration of the trial and beyond for thirty years.   The 
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model follows a standard structure of HF5-7 where each month a HF patient has a risk of either 
surviving without further complication, becoming hospitalized, or dying.  (Figure 1).  
Patient Population  
We modeled a population that was similar to that in the PARADIGM-HF trial which was a 
double blind, randomized, active controlled trial which assessed the impact of the angiotensin 
receptor neprilysin inhibitor sacubitril/valsartan compared with enalapril on cardiovascular 
mortality and HF hospitalizations in patients with left ventricular ejection fraction LVEF d 40% 
and New York Heart Association (NYHA) Functional Class II-IV HF.  The details of inclusion and 
exclusion and the study design have been previously reported8. Patients were followed for a 
median of 27 months. The primary outcome was death from cardiovascular causes or HF 
hospitalization, and data from all hospitalizations were recorded.  
 
Intervention effects and model assumptions 
Separate hazard ratios for all cause-mortality, HF hospitalizations, non-HF hospitalizations, and 
absolute risk of dying and being admitted were calculated and are reported in Table 1.  All-
cause mortality for the patients with HF follows a hazard function based on the PARADIGM-HF 
trial data.   We further compared our model's life expectancy results to an analysis using age-
based Kaplan-Meier methods that was used to project long-term survival rates9 and was 
validated with data from the Studies of Left Ventricular Dysfunction (SOLVD)-Treatment trial 
which also used enalapril. This baseline function approximates a monthly mortality probability of 
0.008 for those in the enalapril arm with a mean age of 63.8 years.  The hazard ratio of 0.84 for 
all-cause mortality in the patients who receive sacubitril/valsartan is then applied to the baseline 
rate.  As a sensitivity analysis, we also applied a Gompertz function based on the trial data to 
see if this had an impact on the overall results. The monthly probability of both non-HF and HF-
hospitalizations were based on the United States subset of the trial data and were 
approximately 0.049 and 0.022 respectively for those in the enalapril arm.  The hazard ratio for 
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reductions in hospitalizations for those receiving sacubitril/valsartan was 0.79 for HF admissions 
and 0.92 for non-HF admissions which was taken from the overall trial results.   
Costs and Utilities 
Costs included both cost of the medications as well as the downstream costs of hospitalizations 
that occurred in each group of simulated patients. Medication costs were based on the 
wholesale acquisition cost for sacubitril/valsartan (trade name Entresto™) and enalapril. The 
monthly cost for the medications were $375 and $7.96 for sacubitril/valsartan and enalapril 
respectively.10  Hospital costs combined Medicare and private insurance rates. 11,12 The mean 
cost of HF and non-HF hospitalizations were $18,158 and $10,467 respectively.  
Quality of life (QOL) or utility decrements were applied each month a person spent in the HF 
state and were based on EQ-5D scores from the trial. Determination of the utility for each 
strategy was determined following a mixed model based on baseline EQ-5D responses, follow-
up responses, hospitalizations, baseline age, and time from start of trial. Values in table 1 
represent utilities for a person with the mean age at the beginning of  the trial.  Further details of 
the EQ-5D model are provided in the Appendix. 
Base-Case Cost-effectiveness Analysis 
We projected the lifetime discounted HF-related health care costs and quality-adjusted 
life years (QALYs) accrued under the two treatment options.  Incremental cost-effectiveness 
ratios (ICERs) were calculated per conventional cost-effectiveness analysis (CEA) guidelines.13 
Costs and QALYs were each discounted at 3% as recommended by the U.S. Panel on Cost-
Effectiveness in Health and Medicine.14 We applied commonly accepted cost-effectiveness 
thresholds of $50,000/QALY, $100,000/QALY, and $150,000/QALY to determine the optimal 
strategy in base-case and sensitivity analyses. 15 
Sensitivity analysis 
We varied values for all variables (or groups of related variables) through plausible ranges, or 
used alternative values, to assess the robustness of our CEA results to changes in these input 
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parameters.  Sensitivity analyses were performed on key inputs including: hospital cost, 
mortality benefit, use of a Gompertz function for mortality, HF hospitalization reduction, drug 
costs, and QOL.  The model was run using DATA TreeAge Pro version: 2015. Finally, we 
conducted a second order probabilistic sensitivity analysis based on 1000 iterations using 
distributions appropriate to the variable16: beta distributions for health probabilities bounded by 
zero and one, log-normal distributions for the hazard ratios, and gamma distributions for the 
costs.   
 
RESULTS 
Model validation and clinical results 
The mean age of our population was 63.8 years of age. At the end of the PARADIGM-HF trial 
with a mean follow-up of 27 months, 17% of the sacubitril/valsartan and 19.8% of the enalapril 
arm had died.  In our model, at 29 months we predict that 17.1% of the sacubitril/valsartan 
population and 19.9% of the enalapril population would die, respectively.    The average survival 
time without discounting in the model was estimated to be 9.65 years in the enalapril arm and 
11.08 years in the sacubitril/valsartan arm.  In a separate analysis using actuarial methods, 
PARADIGM-HF investigators estimated the survival times of a 65-year-old to be similar at 10.2 
and 11.5 years respectively for those taking enalapril and sacubitril/valsartan, respectively. 9 
At the end of the thirty years of simulation, greater than 95% of the model population was 
deceased in each arm making it essentially a life time horizon analysis. 
 
For every 1000 HF patients treated with sacubitril/valsartan, approximately 220 HF admissions 
were averted over the course of their lifetime.  However, given that the population declined more 
rapidly in the enalapril strategy (Figure 2) due to increased total mortality, the potential for HF 
admissions savings in the latter years diminished.  When adjusted for time alive in the model 
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there were 59.7 HF admissions averted per each year alive per 1000 patients in the 
sacubitril/valsartan strategy compared to the enalapril strategy.   
 
Cost-effectiveness analysis 
In a given year, a 1000 patients receiving sacubitril/valsartan would cost approximately 
$4,400,000 more in differential drug costs. In the same year the reductions in hospitalizations 
would lead to a savings of $1,300,000 when compared to receiving enalaprily.   The cost per 
patient over the average life expectancy is approximately $83,300 per patient in the enalapril 
arm and $118,500 in the sacubitril/valsartan treated patients.  After adjustments for quality of life 
the difference in health effects is 0.78 quality-adjusted life years (Table 2). Compared to 
enalapril, the strategy of using sacubitril/valsartan had an incremental cost-effectiveness ratio 
(ICER) of $45,017 per QALY gained. 
 
Sensitivity analyses 
In all the sensitivity analyses presented in the tornado diagram (Figure 3) the ICER remained 
under $100,000/QALY.  When the mortality hazard was tested over the 95% confidence interval 
(CI) from the trial the ICER ranged from as low as $35,357/QALY to as high as $75,301/QALY 
gained.  The HF hospitalization hazard benefit was tested across the 95% CI seen in the trial 
and showed a lower range of sensitivity results with ICERs ranging only from $40,874/QALY to 
$50,212/QALY gained.   When we applied the Gompertz mortality function instead of the 
Kaplan-Meier based function the ICER changed minimally to $48,322/QALY. 
 
The results were not very sensitive to the cost of either drug.  When we tested the cost of 
sacubitril/valsartan across an annual cost of $3375 to $5675 the ICER ranged from 
$35,696/QALY to $56,805/QALY.  When we tested the cost of enalapril from its highest ($1000) 
to lowest ($48) annual cost the ICER ranged from $35,403/QALY to $45,481/QALY gained.  
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When the cost of HF hospitalization was tested from an average of $12,000 to approximately 
$27,000 per hospitalizations, there was little impact on the ICER, ranging from a low of 
$42,618/QALY to $46,726/QALY.  Finally, when we assessed the quality of life benefit across its 
95% CI from the trial the ICER ranged from $42,869 to $47,480/QALY. When we assumed no 
utility benefit the ICER was $49,603/QALY. All of these results are considered a “very good 
value” (<$50,000/ QALY) to a “good value” (< $150,000/QALY) using both American College of 
Cardiology/American Heart Association (ACC/AHA) and World Health Organization (WHO) 
standards. The probabilistic sensitivity analysis revealed a mean value of $47,519/QALY with 
95% of the values between $34,751 and $71,039/QALY.  Further, we tested the assumption 
that the medication benefit persists with the same relative risk reduction beyond the trial. In one 
case we assume a linear decay of treatment to where it has no effect at the end of 30 years and 
one in which the linear decay is to half of its effectiveness at 30 years. In the scenario of linear 
decay to no benefit the ICER is $53,970/QALY.  In the scenario when the decay is to the level of 
half of the reported trial benefit the ICER is $49,232/QALY.  When we modeled the extreme 
case of the benefit only lasting 27 months as opposed to 360 months, the ICER for 
sacubitril/valsartan compared to enalapril was $135,964/QALY which remained below the 
willingness to pay threshold of $150,000/QALY 
 
DISCUSSION 
Our model-based analyses suggest that the health benefits associated with the use of 
sacubitril/valsartan in patients with Class II-IV HFrEF HF is cost-effective when compared to the 
use of enalapril at commonly accepted willingness to pay thresholds of $50,000/QALY gained.  
Furthermore, use of sacubitril/valsartan could lead to over a year of life gained per patient using 
the medication and significant cost savings through avoided hospitalizations. Because of this 
additional life expectancy with 5.7 million individuals in the US with HF1, the benefits of 
expanded use of sacubitril/valsartan could be large.  Given up to half of the population with HF 
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are HFrEF patients, a considerable number would be potentially eligible for the medication 
based on the trial criteria.17-19 For every 100,000 people receiving sacubitril/valsartan, this 
strategy could potentially reduce hospitalizations by 3000 and reduce deaths by nearly the 
same number over a two year period. Medical savings from reduced HF admissions would be 
over $27 million.  
The ICER of $45,017/QALY is not only below standard accepted levels for evaluations of 
new therapies and interventions, its value also compares well with other accepted 
cardiovascular therapies when they were first adopted or approved.  For example, the 
incremental cost-effectiveness ratio (ICER) for pravastatin before it became generic was 
$54,000 to $1,400,000/QALY gained20 with similar results for other statins.21,22  In addition, 
ICERs for implantable cardioverter defibrillators with and without cardiac resynchronization 
therapy range from $35,000 to $108,000/QALY23,24 while the ICERs for percutaneous coronary 
interventions are around $36,000/QALY25 and the ICER for left ventricular  assist devices range 
from $120,000 to over $300,000/QALY gained.26  
 
With the exception of one extreme case, all of the sensitivity analyses revealed ICERs 
below $76,000/QALY. The results are robust over a range of different assumptions in the 
sensitivity analyses for several reasons. First, HF is a condition with significant mortality with a 
median survival of less than 5 years of those on optimized treatment in previous assessments27-
29. Any treatment that can reduce this mortality by 15-20% is likely to be cost-effective across a 
reasonable price range.  Second, HF patients along with their other frequent co-morbidities are 
at risk for multiple admissions. In the PARADIGM-HF trial patients with optimized treatment 
were still admitted on average 1 time per every two years —HF or other cardiovascular cause. A 
15-20% percent reduction in those admissions likely contributes to the relative improvements in 
overall quality of life as decrements in quality of life were associated with admissions.  Third, the 
cost of cardiovascular care including admissions is relatively expensive at $10,000-$27,000 per 
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admission and reductions in these will also be relatively robust to changes in price of the 
intervention. Even with conservative estimates around the parameters used in the model for 
sensitivity analyses, the findings remain cost-effective across a range of estimates in the model 
assumptions at the threshold of $150,000/QALY. This threshold has been justified in part by 
empiric evidence on surveys on willingness to pay for health, revealed preference studies, 
general increases on healthcare spending, in addition to the WHO recognizing three times 
GDP/capita as an upper threshold.15 Further the ACC/AHA have set a similar target equivalent 
to $150,000/QALY gained as of at least intermediate value. 30 Finally, we did not make any 
adjustment for the fact that the cost of sacubitril/valsartan may decrease in 2023 after its patent 
expiration date.  While we are unable to estimate what the cost would change to, any decrease 
in the cost would make the cost-effectiveness ratio for sacubitril/valsartan more favorable. 
 
Other evaluations of sacubitril/valsartan also found the medication to be cost-effective with 
ICERs of approximately $50,000/QALY gained.19,31  The Institute for Clinical and Economic 
Review  obtained an ICER of $50,915/QALY which was very similar to our result. One key 
difference is their use of the lowest cost ACEI at $3 per month where we use the reported costs 
of enalapril at $8/month.  When we did a sensitivity analysis using the lower cost we still found it 
to be cost-effective. A further difference is that we modelled the event rates for hospitalization 
based on the United States subset of the trial which was higher than the other countries in the 
trial. This would lead to reductions in the ICER given the greater opportunity for cost reductions. 
Further, our mortality function reflected the trial experience and did not rely on creating 
estimates using life tables from the National Vital Statistics System for non-cardiovascular 
disease deaths. King et al. found similar results but a difference in their analysis is they included 
New York Heart Association functional class I patients in their model but these patients were 
excluded from the PARADIGM-HF trial. Further they used utility values from another trial as 
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opposed to the PARADIGM_HF trial that was used in our analysis. They also did not include 
non HF admissions. 
 
One limitation included the active run-in of the trial.  Therefore, our results assume that patients 
can tolerate the recommended dose of each medication without an adverse event.  However, 
only 12% of patients did not complete the run-in phase and the rates of adverse advents were 
higher for those receiving enalapril in the run-in. Another limitation is that we did not model 
changes in adverse events directly in the model.  In the PARADIGM-HF trial, the most common 
adverse events included hypotension, cardiac failure, hyperkalemia, renal impairment, and 
cough.  However, discontinuing study medications due to these events was lower in the 
sacubitril/valsartan patients compared to the enalapril patients (10.7 vs 12.3%), further 
highlighting that the results from our analysis may be conservative.  Only episodes of 
symptomatic hypotension (14% vs 9.2%) were higher in the sacubitril/valsartan arm of the trial.  
We did not model reductions in ED visits but these also favored the sacubitril/valsartan arm with 
fewer ED visits for HF.  The risk of angioedema was not statistically significantly elevated in the 
trial and hospitalizations for angioedema were rare (0.1%). Also, there were no cases of 
angioedema requiring intubation for Entresto.  
 
Further, this study only evaluated the cost-effectiveness of sacubitril/valsartan in the United 
States.  While the hazard rates for reductions in hospitalizations and mortality were trial wide, 
the baseline rate of each is different with the highest rates in the United States.  Further costs 
for hospitalizations are different in each country so that individual analyses will need to be 
conducted in other countries.   
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In summary, we found that for eligible patients, sacubitril/valsartan was cost-effective at an 
ICER consistent with other high value accepted CV interventions, such as ICDs and cholesterol 
lowering medications, at a commonly accepted willingness to pay.  
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List of Figures: 
Figure 1. Markov model diagram. 
Legend: Patients occupy health states, shown in ovals. Patients transition from different health states represented as arrows 
based on transition probabilities.  
Figure 2. Survival Curves, According to Treatment Strategy 
 Legend: Shown are estimates of the probability of being alive at any given time over 360 months. 
Figure 3. Tornado diagram 
 Legend: Univariate sensitivity analyses evaluating the impact of each variable’s uncertainty on overall cost-effectiveness ratio. 
The central black line represents the base-case analysis.  None of the analyses lead to an incremental cost-effectiveness ratio 
greater than $150,000/QALY. 
Table 1.  Model Inputs 
Input Value Range Source 
Health      
 Probability of non HF hospitalization (monthly) 0.0487 0.040 - 0.058 Trial3,4 
Probability of HF hospitalization (monthly) 0.0216 0.018 - 0.026 Trial 
Probability of dying (monthly) 0.0081 0.0072- 0.0091 Trial 
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HR* (sacubitril/valsartan vs enalapril)   
 
        Mortality 0.84 0.76 - 0.93 Trial 
        HF Hospitalization 0.79 0.71 - 0.89 Trial 
               Non-HF hospitalization 0.92 0.85 - 0.99 Trial 
Costs 
   
HF hospitalization $18,158  $12,148 - $26595 
Medicare Fee Schedule/Private 
payers12,32 
Non-HF hospitalization $10,467  $7,200 - $12,300 AHRQ33, Pfunter34 
enalapril (annual) $96  $48 - $1080 Red Book10  
sacubitril/valsartan (annual) $4,500  $3375 - $5675 Red Book10  
Utilities** 
   HF_sacubitril/valsartan 0.838 0.833 - 0.843 Trial 
HF_enalapril 0.829 0.824 – 0.834 Trial 
Discount rate 3% 0 - 5% Gold et al. 35 
*HR – Hazard ratio 
**Utilities were calculated based on mixed effects model based on  EQ-5D scores reported at baseline and over time during the trial. 
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Model utilities were a function of baseline EQ-5D scores, age, time, hospitalization, and treatment status.  Values reported in table 
are utilities for an average age patient in the first year of the model. Further details are available in an appendix.  
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Table 2.  Total costs, health effects and incremental cost-effectiveness ratio (ICER) 
 
 
     
  
Total Costs 
Incremental 
Costs  
Total QALYs 
Incremental 
QALYS 
ICER 
($/QALYS) 
Enalapril $83,303 _ 6.02 _ 
 
Sacubitril/Valsartan $118,815 
 
6.80 
    - $35,207 - 0.78 45,017 
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